Nome do produto:Vapreotide,Octastatin,Vapreotide
Sequência: D-Phe-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2
Alias:Sanvar,RC-160;VAPREOTIDE;D-PHE-CYS-TYR-D-TRP-LYS-VAL-CYS-TRP-NH2; Octastatin;
FCYWKVCW-NH2;D-Phe-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Trp-NH2;
Cas Não.: 103222-11-3
Fórmula Molecular: C57H70N12O9S2
Peso molecular: 1131.40
Pureza (HPLC): 98.0%
Aparência: Pó branco
Impureza Única(HPLC): 1.0%
Composição de aminoácidos: 10% de teórico
Conteúdo Peptídico(N%): 80%(por %N)
Conteúdo de água(Carlos Fischer): 6.0%
Conteúdo de acetato(HPIC): 15.0%
Balanço de Massa: 95.0~105,0%
Nota : Grau Farmacêutico
Armazenar: Fechado, abaixo 2 ~ 8℃ preservation
Uso : The drug can be used for treatment of early acute esophageal variceal bleeding (EVB) and endoscopic interventional therapy before hemostasis, can also be bleeding within 5 d lens for the treatment and prevention of recurrence after endoscopic.vapreotide acetate will be the only approved treatment for esophageal variceal bleeding in the United States.
Variceal bleeding is a life-threatening complication of portal hypertension. The recommended treatment includes the early administration of a vasoactive drug. Vapreotide is a somatostatin analogue with a different receptor affinity to octreotide. It decreases portal pressure and blood flow of collateral circulation in rats with cirrhosis. The pivotal study of early administration of vapreotide in patients with cirrhosis and variceal bleeding has shown a significant improvement in bleeding control and, in the subset of patients with significant bleeding, a significant reduction in mortality. Além disso, a meta-analysis of four randomized studies has shown a significant improvement in bleeding control. Vapreotide administrated via the intravenous route is simple to use, with practically no contraindications and few, usually minor, side effects.
The immediate release formulation of Sanvar, a somatostatin analogue, is used in the treatment of acute esophageal variceal bleeding (EVB).Sanvar is used prior to endoscopic intervention to control haemorrhage and prevent re-bleeding during the critical five days following the onset of bleeding. EVB is a life threatening condition and the mortality rate is high (about 15% para 25%) in the first six weeks following the haemorrhage. EVB is the cause of about 70% of gastro-intestinal bleeding in patients suffering from liver cirrhosis.
